UBS Group’s Altamira Therapeutics Ltd CYTO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,711
| Closed | -$1.9K | – | 10512 |
|
|
2024
Q2 | $1.9K | Buy |
+1,711
| New | +$2.62K | ﹤0.01% | 8463 |
|
|
2024
Q1 | – | Sell |
-6,814
| Closed | -$23.7K | – | 10450 |
|
|
2023
Q4 | $23.7K | Buy |
+6,814
| New | +$29.7K | ﹤0.01% | 7002 |
|
|
2023
Q2 | – | Sell |
-77
| Closed | -$1.96K | – | 10123 |
|
|
2023
Q1 | $1.96K | Sell |
77
-115
| -60% | -$6.61K | ﹤0.01% | 8616 |
|
|
2022
Q4 | $18.7K | Buy |
192
+172
| +860% | +$20K | ﹤0.01% | 7724 |
|
|
2022
Q3 | $2K | Sell |
20
-45
| -69% | -$7.47K | ﹤0.01% | 9839 |
|
|
2022
Q2 | $13K | Buy |
65
+56
| +622% | +$18.1K | ﹤0.01% | 7591 |
|
|
2022
Q1 | $4K | Sell |
9
-9
| -50% | -$4.35K | ﹤0.01% | 9368 |
|
|
2021
Q4 | $13K | Buy |
18
+8
| +80% | +$5.36K | ﹤0.01% | 8492 |
|
|
2021
Q3 | $8K | Buy |
10
+6
| +150% | +$6.76K | ﹤0.01% | 8245 |
|
|
2021
Q2 | $5K | Buy |
+4
| New | +$5.49K | ﹤0.01% | 8596 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 9642 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 8907 |
|
|
2020
Q3 | – | Sell |
-3
| Closed | -$1.13K | – | 8556 |
|
|
2020
Q2 | $1K | Sell |
3
-16
| -84% | -$6.01K | ﹤0.01% | 7831 |
|
|
2020
Q1 | $6K | Buy |
+19
| New | +$9.36K | ﹤0.01% | 7251 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | -$1.36K | – | 8515 |
|
|
2019
Q3 | $2K | Buy |
+2
| New | +$2.21K | ﹤0.01% | 7768 |
|
|
2019
Q2 | – | Sell |
-2
| Closed | -$6K | – | 8252 |
|
|
2019
Q1 | $6K | Buy |
2
+1
| +100% | +$3.21K | ﹤0.01% | 7115 |
|
|
2018
Q4 | $3K | Buy |
+1
| New | +$5.11K | ﹤0.01% | 7749 |
|
|
2018
Q3 | – | Sell |
-2
| Closed | -$10K | – | 8357 |
|
|
2018
Q2 | $10K | Buy |
+2
| New | +$21.1K | ﹤0.01% | 7153 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7573 |
|
|
2017
Q3 | – | Hold |
0
| – | -$22K | – | 8090 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6238 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7320 |
|
|
2016
Q3 | – | Hold |
0
| – | -$33K | – | 8008 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5866 |
|
|
2016
Q1 | – | Hold |
0
| – | -$7K | – | 8340 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7539 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6653 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6459 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 8253 |
|
Other funds holding CYTO
UBS Group's CYTO Position: Q3 2024 in Review
UBS Group sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2024, closing a stake of 1,711 shares — an estimated $1.9K sold.
UBS Group first reported a position in CYTO in Q2 2018 and held it in 16 quarters. The position peaked at $23.7K in Q4 2023. 5 funds tracked by Wall St. Rank hold CYTO as of Q3 2024.
- UBS Group reported no remaining Altamira Therapeutics Ltd position as of Q3 2024 after selling out during the quarter.
- UBS Group sold 1,711 Altamira Therapeutics Ltd shares in Q3 2024, an estimated $1.9K.
- UBS Group first reported a position in Altamira Therapeutics Ltd in Q2 2018 and held it in 16 quarters.
- UBS Group's Altamira Therapeutics Ltd position peaked at $23.7K in Q4 2023.
- 5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2024.
Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.